Table 3.
Summary of Atherosclerosis Risk In Communities visit 2 participants characteristics
| Characteristic | Non-DM (n=9407) |
DM (n=1623) |
|---|---|---|
| Age, yr (SD) | 56.8 (5.7) | 58.1 (5.7) |
| Male (%) | 4108 (43.7) | 977 (45.5) |
| Black, n (%) | 1849 (19.7) | 646 (39.8) |
| DM, n (%) | 0 (0) | 1623 (100) |
| HTN, n (%) | 2948 (31.3) | 950 (58.5) |
| Antihypertensive medication, n (%) | 2139 (22.7) | 808 (49.8) |
| Prevalent CVD, n (%) | 595 (6.3) | 241 (14.8) |
| Current smoker, n (%) | 2128 (22.6) | 302 (18.6) |
| Former smoker, n (%) | 3543 (37.7) | 625 (38.5) |
| Total cholesterol, mmol/L (SD) | 5.4 (1.0) | 5.5 (1.2) |
| HDL cholesterol mmol/L (SD) | 1.3 (0.4) | 1.1 (0.4) |
| BMI, kg/m2 (SD) | 27.3 (5.0) | 31.2 (5.9) |
| SBP, mm Hg (SD) | 120 (18) | 128 (20) |
| eGFRcrcys, ml/min per 1.73 m2 (SD) | 99 (16) | 95 (20) |
| eGFR 50% decline, n (%) | 1190 (12.7) | 354 (21.8) |
| Follow-up to eGFR 50% decline years (range) | 24.6 (17.8–27.7) | 18.3 (10.4–24.2) |
| Incident ESKD, n (%) | 131 (1.4) | 153 (9.4) |
| Follow-up to ESKD years (range) | 25.7 (18.0–27.9) | 18.5 (11.0–25.5) |
Data are presented as mean (SD), median (range), or n (%). DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; eGFRcrcys, eGFR on the basis of creatinine and cystatin C.